Publications by authors named "M F M De Bock"
Globally, nearly 9 million people are living with type 1 diabetes (T1D). Although the incidence of T1D is not affected by socioeconomic status, the development of complications and limited access to modern therapy is overrepresented in vulnerable populations. Diabetes technology, specifically continuous glucose monitoring and automated insulin delivery systems, are considered the gold standard for management of T1D, yet access to these technologies varies widely across countries and regions, and varies widely even within high-income countries.
View Article and Find Full Text PDFISPAD Clinical Practice Consensus Guidelines 2024: Glycemic Targets.
Horm Res Paediatr
December 2024
of what is New or Different 1. This chapter recommends a target HbA1c of ≤6.5% (48mmol/mol) for those who have access to advanced diabetes technologies like continuous glucose monitoring (CGM) and automated insulin delivery (AID).
View Article and Find Full Text PDFArticle Synopsis
- Oral PrEP is highly effective in reducing HIV risk by 99% during sex and by at least 74% for people who inject drugs, and UNAIDS aims for 21.2 million individuals using PrEP by 2025.
- The CDC has played a significant role in global PrEP implementation since 2016, achieving over 2.2 million initiations from 2017 to 2023, mostly among women and young people in sub-Saharan Africa.
- Despite the progress, ongoing efforts are crucial to meet UNAIDS targets and ultimately eliminate HIV as a public health threat.
Results of an Australian trial of an automated insulin delivery (AID) system and other studies support likely benefit of AID use for many Australian adults with type 1 diabetes.
Intern Med J
November 2024
Less than 20% of Australians with type 1 diabetes (T1D) meet recommended glucose targets. Technology use is associated with better glycaemia, with the most advanced being automated insulin delivery (AID) systems, which are now recommended as gold-standard T1D care. Our Australian AID trial shows a wide spectrum of adults with T1D can achieve recommended targets.
View Article and Find Full Text PDFAims: To identify from a parental perspective facilitators and barriers of effective implementation of advanced hybrid closed-loop (AHCL) therapy in children and adolescents with type 1 diabetes (T1D) with elevated glycaemia.
Methods: Semi-structured interviews were conducted with parents of participants while in a post-trial extension phase of the CO-PILOT randomized controlled trial. The Capability, Opportunity, Motivation, Behaviour Model and Theoretical Domain Framework informed the interviews and framework analysis.